Last reviewed · How we verify

NCT07441811

Urine Albumin/Creatinine Ratio and Renal Function Differences in Phenotypes of Polycystic Ovary Syndrome.

Completed Last updated 2 March 2026
What this trial tests

trial in Polycystic Ovary Syndrome in 300 participants. Completed in 20 July 2023.

Timeline
1 April 2022
Primary endpoint
1 September 2022
20 July 2023

Quick facts

Lead sponsorUşak University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment300
Start date1 April 2022
Primary completion1 September 2022
Estimated completion20 July 2023
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Uşak University

Who can join

Adults 18 to 35, female only, with Polycystic Ovary Syndrome or Urine Albumin \(UAlb\). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since there are different metabolic effects in different phenotypes of polycystic ovary syndrome (PCOS); in this study; the investigators aimed to investigate whether there is a difference between glomerular filtration rate (eGFR) and urine albumin/creatinine ratio (ACR) levels in different PCOS phenotypes and compare healthy controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Polycystic Ovary Syndrome

Currently open trials in the same condition.

Other Uşak University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07441811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing